ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.BMC cancer · 2022Pooled it
- Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.The oncologist · 2019Review
- Sequence of treatment in locally advanced and metastatic renal cell carcinoma.Translational andrology and urology · 2015Review
Corrections and comments
- Comment on
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24019543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.